Coyote’s GGA technology platform offers the potential to address numerous high-need indications and high-value market opportunities.  Coyote’s extensive research of GGA, a known compound with a proven safety profile, has enabled the company to build a unique, yet integrated therapeutic and drug delivery strategy.

CNS-102 works through a novel mechanism of action that is distinct from other drugs designed to treat degenerative diseases. The potent neuroprotective effects of CNS-102 have been established in animal models of ALS (Lou Gehrig’s disease) and Alzheimer’s disease, and are being extended to treat retinal degenerative diseases, including glaucoma, via a patented eye drop formulation. 

GGA possesses unique physiochemical properties that enhance the sublingual delivery of other drugs. Coyote’s aim is to partner with pharmaceutical companies to transform injectable products into sublingually delivered compounds that vastly enhance the drugs’ appeal and commercial potential.